Confirmatory Study of Govorestat in CMT-SORD

Summary

This study is designed to assess the long-term efficacy and clinical benefit of AT-007 in patients with CMT-SORD. This randomized, double-blind study will assess the effect of govorestat compared to placebo in patients with CMT-SORD for up to 36 months.

Timeline

Start

2026-05

Primary completion

2028-10

Completion

2029-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study was withdrawn prior to enrollment as the sponsor decided not to proceed with study initiation.”

Drugs

Indications